Applied Cells and Immuneel Therapeutics Partner to Develop Affordable CAR-T Therapies for India and Global Markets
核心洞察
Applied Cells Inc. (搜索) and Immuneel Therapeutics (搜索) have entered into a strategic collaboration to integrate the MARS® Atlas platform and GoFast™ CAR-T workflow into select CAR-T programs.
The partnership aims to significantly improve affordability and accessibility of CAR-T treatments for cancer patients, starting in India with plans for broader global adoption.
Key objectives include achieving manufacturing costs that enable truly affordable CAR-T therapy for the majority of eligible patients in India while maintaining excellent therapeutic efficacy relative to approved treatments.
Applied Cells Inc. (搜索) and Immuneel Therapeutics (搜索) Private Limited announced a strategic collaboration framework to jointly evaluate the application of Applied Cells' MARS® Atlas platform and GoFast™ CAR-T workflow for future CAR-T therapy development and manufacturing opportunities. The partnership focuses on significantly improving affordability and accessibility of CAR-T treatments for cancer patients, beginning in India with the aim of broader global adoption.
Manufacturing Cost Reduction Strategy
Under the collaboration, the parties will work together on integration of the MARS® Atlas platform and GoFast™ workflow into select Immuneel CAR-T programs. Key objectives include achieving manufacturing costs that enable truly affordable CAR-T therapy for the majority of eligible patients in India, while maintaining excellent therapeutic efficacy relative to approved CAR-T treatments.
"We are thrilled to partner with Immuneel, a pioneer in bringing cutting-edge cell therapies to India," said Yuchen Zhou, CEO of Applied Cells. "The combination of MARS® Atlas and the GoFast™ workflow with Immuneel's clinical and regulatory capabilities has the potential to transform the CAR-T landscape by making these life-saving treatments accessible to millions who currently cannot afford them."
Technology Integration and Platform Capabilities
Applied Cells' flagship MARS® Atlas platform with GoFast™ CAR-T workflow is designed to dramatically reduce cost and time of CAR-T manufacturing while maintaining the highest quality standards. The automated cell separation and preparation solutions target cell therapy development and manufacturing processes.
Amit Mookim, CEO of Immuneel Therapeutics (搜索), emphasized the collaboration's significance: "At Immuneel, our mission is to make advanced cell therapies accessible and affordable for patients who need them the most. This collaboration represents an important step in evaluating innovative technologies that could strengthen our manufacturing capabilities and support development of scalable, cost-effective CAR-T solutions."
Global Market Expansion Plans
The partnership positions both companies to explore how platforms like MARS® Atlas and the GoFast™ workflow could contribute to expanding access to high-quality cell therapies in India and beyond. Immuneel Therapeutics (搜索), a clinical-stage biotechnology company, focuses on developing affordable, best-in-class cell and gene therapies, with particular emphasis on CAR-T therapies for cancer patients in India and emerging markets.
Both companies have commenced collaborative activities and will provide further updates as the programs progress. The collaboration framework represents a strategic approach to building a sustainable end-to-end cell therapy ecosystem that delivers world-class treatments at accessible price points.